平喘止咳合剂辅助治疗小儿支气管肺炎痰热闭肺证64例临床观察  

Clinical observation on 64 cases of pediatric bronchopneumonia with phlegm heat obstructing the lung pattern treated with Pingchuan Zhike Heji(平喘止咳合剂)as an adjuvant therapy

作　　者：张小聪 ZHANG Xiaocong(Department of Pediatrics,Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University,Hangzhou,Zhejiang,310022,China)

机构地区：[1]浙江中医药大学附属杭州市中医院儿科,浙江杭州310022

出　　处：《中医儿科杂志》2024年第5期70-74,共5页Journal of Pediatrics of Traditional Chinese Medicine

摘　　要：目的观察平喘止咳合剂辅助治疗小儿支气管肺炎痰热闭肺证的临床疗效。方法选取2021年9月至2022年9月浙江中医药大学附属杭州市中医院儿科收治的128例支气管肺炎痰热闭肺证患儿,按照随机数字表法分为治疗组和对照组,各64例。对照组采用西医常规治疗,治疗组在对照组治疗方法的基础上联合平喘止咳合剂口服。2组均7 d为1个疗程,治疗1个疗程后统计临床疗效。结果治疗组的总有效率为95.31%(61/64),显著高于对照组的84.38%(54/64),2组比较,差异有统计学意义(P<0.05)。治疗组气促、咳嗽咳痰、发热及肺部啰音消失时间均显著短于对照组,2组比较,差异均有统计学意义(P<0.01)。治疗前2组的血清超敏C反应蛋白(hs-CRP)、降钙素原(PCT)水平比较,差异无统计学意义(P>0.05),具有可比性;治疗后2组的血清hs-CRP、PCT水平均显著下降,与同组治疗前比较,差异有统计学意义(P<0.05),且治疗组降低更显著(P<0.05或P<0.01)。治疗过程中,对照组出现1例呕吐,治疗组皮肤过敏和皮疹均1例,但均不影响治疗,2组比较,差异无统计学意义(P>0.05)。结论平喘止咳合剂辅助治疗小儿支气管肺炎痰热闭肺证,不仅能有效缓解患儿临床症状,促进肺部病灶的吸收,改善局部炎症反应,且临床疗效显著,值得临床推广应用。Objective To observe the clinical efficacy of Pingchuan Zhike Heji(平喘止咳合剂)as an adjuvant therapy in the treatment of pediatric bronchopneumonia with phlegm heat obstructing the lung pattern.Methods A total of 128 pediatric patients with bronchopneumonia of phlegm heat obstructing the lung pattern who were treated in the Department of Pediatrics,Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University from September 2021 to September 2022 were selected and randomly divided into a treatment group and a control group,with 64 patients in each group.The control group received conventional Western medical treatment,while the treatment group was given Pingchuan Zhike Heji orally in addition to the treatment in the control group.Both groups were treated for 7 days as one course of treatment,and the therapeutic effects were evaluated after one course of treatment.Results The total effective rate in the treatment group was 95.31%(61/64),significantly higher than 84.38%(54/64)in the control group,with a statistically significant difference between the two groups(P<0.05).The time for the disappearance of symptoms such as shortness of breath,cough and expectoration,fever,and lung rales was significantly shorter in the treatment group compared to the control group,with statistically significant differences between the two groups(P<0.01).Before treatment,there were no significant differences in serum hypersensitive Creactive protein(hs-CRP)and procalcitonin(PCT)levels between the two groups(P>0.05),indicating comparability.After treatment,the serum hs-CRP and PCT levels in both groups were significantly decreased compared to before treatment,with statistically significant differences(P<0.05),and the decrease was more pronounced in the treatment group(P<0.05 or P<0.01).During the treatment,there was 1 case of vomiting in the control group and 1 case of skin allergy and rash in the treatment group,but none of these affected the treatment,and there was no statistically signifi

关 键 词：支气管肺炎 小儿 痰热闭肺证 平喘止咳合剂 临床观察 

分 类 号：R256.1[医药卫生—中医内科学]